Alkermes is a global biopharmaceutical company, founded in 1987, focused on developing innovative medicines for neuroscience. The company's portfolio includes commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, as well as a pipeline of candidates for neurological disorders. Alkermes' dedication to patient-inspired science, integrated research, and development capabilities, along with a specialized commercial infrastructure, positions it to pursue the development and commercialization of new medicines, especially for conditions that have been historically overlooked. The company's commitment to patient engagement, responsible operations, and equitable treatment access underscore its holistic approach to supporting patients and caregivers. Their headquarters in Ireland, with offices and research centers in Massachusetts and a manufacturing facility in Ohio, reflect their global presence. The most recent Post-IPO Equity investment was made on 20 November 2017, with Primecap Management as the investor.
Alkermes is set apart by its deep expertise in neuroscience, as evidenced by its robust pipeline of clinical and preclinical candidates for neurological disorders. The company's focus on developing medicines for traditionally overlooked or stigmatized conditions reflects its commitment to addressing unmet medical needs. Moreover, Alkermes' emphasis on patient empathy and urgency in developing new treatment options demonstrates its dedication to improving the lives of those affected by neurological and psychiatric disorders. The company's multi-locational presence across Ireland, Massachusetts, and Ohio indicates its strategic positioning in key biopharmaceutical hubs.
The Post-IPO Equity investment at 20 November 2017, led by Primecap Management, signifies a vote of confidence in Alkermes' potential for future growth and innovation in the biopharmaceutical sector. The investment validates Alkermes' market presence and its strategies for advancing treatment options in neuroscience. This infusion of capital can enable the company to further its research and development efforts, expand its commercial reach, and continue its mission of developing innovative medicines for complex neurological and psychiatric disorders.
Taxonomy:
Biopharmaceutical, Neuroscience, Medicines, Psychiatric Disorders, Neurological Disorders, Alcohol Dependence, Opioid Dependence, Schizophrenia, Bipolar I Disorder, Clinical Research, Preclinical Research, Patient-Centered, Global Operations, R&D Center, Manufacturing Facilities
Ireland
